Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 8/20 | 0.40 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | IKBKG | Q9Y6K9 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12589838 | 0.87 | MAPK14 (0.49) | L3MBTL3ALDH1A1L3MBTL1KDM4ENPC1 | |
| SCHEMBL1596435 | 0.86 | ALDH1A1 (0.64) | L3MBTL3ALDH1A1L3MBTL1KDM4ENPC1 | |
| SCHEMBL12589839 | 0.85 | ALDH1A1 (0.44) | L3MBTL3ALDH1A1L3MBTL1KDM4ENPC1 | |
| SCHEMBL12589845 | 0.84 | ALDH1A1 (0.40) | L3MBTL3ALDH1A1L3MBTL1KDM4ENPC1 | |
| SCHEMBL12589837 | 0.84 | ALDH1A1 (0.41) | L3MBTL3ALDH1A1L3MBTL1KDM4ENPC1 | |
| SCHEMBL17624645 | 0.83 | MAPT (0.47) | L3MBTL3ALDH1A1L3MBTL1KDM4ENPC1 | |
| SCHEMBL19396257 | 0.83 | L3MBTL3 (0.62) | L3MBTL3ALDH1A1L3MBTL1 | |
| SCHEMBL12589842 | 0.83 | SCD5 (0.46) | ALDH1A1L3MBTL1KDM4ENPC1RAB9A | |
| SCHEMBL19396275 | 0.81 | ALDH1A1 (0.43) | ALDH1A1KDM4ENPC1RAB9AMAPK14 | |
| SCHEMBL19396258 | 0.80 | CYP2C9 (0.51) | ALDH1A1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170273968-A1 | MAO-B INHIBITORS AND REHABILITATION | DART NEUROSCIENCE, LLC | 2017-09-28 | — | — | US | disclosed |
| US-8399487-B2 | Pyrazole compounds and uses thereof | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-03-19 | — | — | US | disclosed |
| US-20110160248-A1 | PYRAZOLE COMPOUNDS AND USES THEREOF | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160248-A1 | PYRAZOLE COMPOUNDS AND USES THEREOF | MAOB, MAOA, HTR1B | L3MBTL3 2677/4885ALDH1A1 602/4885L3MBTL1 2501/4885 |
| US-20170273968-A1 | MAO-B INHIBITORS AND REHABILITATION | MAOB, MAOA, HTR2B | L3MBTL3 2937/4885ALDH1A1 1300/4885L3MBTL1 2981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.